Predictivity of Fatty Liver Index for Non-Alcoholic Fatty Liver Disease in Lean Females with Polycystic Ovary Syndrome
April 2022
in “
African Health Sciences
”
TLDR The Fatty Liver Index (FLI) may not be enough to rule out non-alcoholic fatty liver disease in lean women with polycystic ovary syndrome.
The study conducted from January 2014 to January 2016 involved 83 premenopausal women with polycystic ovary syndrome (PCOS) and 58 controls to investigate the predictivity of the Fatty Liver Index (FLI) for non-alcoholic fatty liver disease (NAFLD) in lean and overweight/obese females with PCOS. The results showed that γ-glutamyl transferase levels were significantly higher in females with PCOS than in the controls (p = 0.001), and FLI was significantly higher in females with NAFLD compared to those without NAFLD (47.1 ± 33.6 vs. 16.9 ± 21.6; p = 0.001). Body Mass Index had the strongest relationship with FLI in the PCOS group (p < 0.05, r = 0.908). Lean females with PCOS had a significantly higher rate of NAFLD (27.5% vs. 8.8%; p = 0.041) than lean controls. The study concluded that an FLI < 30 was not sufficient to rule out NAFLD in lean PCOS patients.